Table 4.
Regimens and results of salvage treatment for local recurrent or residual squamous cell carcinoma of the esophagus
| Patient | Response for CCRT | Time to treatment failure (months) |
Salvage treatment | Outcome | Duration # (months) |
Survival from CCRT (months) |
|---|---|---|---|---|---|---|
| Residual cancer group | ||||||
| 1 | SD | 12.40 | TP→FOLFIRI | Dead of disease | 54.90 | 73.30 |
| Local failure at primary site group | ||||||
| 2 | PR | 13.40 | TP | Dead of disease | 0.30 | 13.80 |
| 3 | SD | 77.43 | TP + Radiotherapy | Dead of disease | 28.93 | 108.20 |
| 4 | PR | 83.53 | S-1 + Apatinib | Dead of disease | 23.10 | 107.07 |
| 5 | CR | 20.77 | Capecitabine | Dead of disease | 13.27 | 34.17 |
| 6 | CR | 27.80 | Surgery | Dead of disease | 54.97 | 83.20 |
| 7 | CR | 14.90 | TP + Surgery | Dead of disease | 10.63 | 26.27 |
| 8 | PR | 137.23 | S-1 | Alive with disease | 0.70 | 138.27 |
| 9 | PR | 10.07 | Surgery | Dead of disease | 12.17 | 23.63 |
| 10 | PR | 22.13 | TP | Dead of disease | 8.90 | 31.43 |
| 11 | CR | 27.43 | Radiotherapy + S-1→TP + anti-PD-1 antibody→ Radiotherapy | Dead of disease | 37.13 | 65.37 |
| 12 | PR | 6.40 | Capecitabine | Dead of disease | 13.50 | 20.03 |
| 13 | PR | 12.00 | surgery | Alive, disease free | 74.60 | 89.60 |
| 14 | CR | 51.40 | TP + Radiotherapy | Alive, disease free | 35.47 | 89.10 |
| Metachronous multiple cancer group | ||||||
| 15 | CR | 49.73 | Radiotherapy + Capecitabine | Alive, disease free | 80.27 | 131.27 |
# The duration was measured from the date of salvage treatment to the date of confirmation of death or the end of follow-up
Abbreviations: CCRT = concurrent chemoradiotherapy; SD = stable disease; PR = partial response; CR = complete response; TP = taxol + platinum; FOLFIRI = 5-fluorouracil + irinotecan + leucovorin; anti-PD-1 = anti-program death-1